Ligand to Host Investor Day on December 9, 2025
Ligand (Nasdaq: LGND) will hold its annual Investor Day on December 9, 2025 in New York City at The Harvard Club from 10:30 a.m. to 12:00 p.m. ET. Management presentations will include CEO Todd Davis and CFO Tavo Espinoza and will cover the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook.
Guest speaker Scott Plesha, CEO of partner Pelthos Therapeutics, will discuss the recent launch of ZELSUVMI (berdazimer) topical gel 10.3%, described as the first FDA-approved at-home treatment for molluscum contagiosum. A live webcast and replay will be available on Ligand’s investor relations website, and investors can register for the event online.
Ligand (Nasdaq: LGND) terrà il suo annual Investor Day il 9 dicembre 2025 a New York, presso The Harvard Club, dalle 10:30 alle 12:00 ora ET. Le presentazioni della direzione includeranno il CEO Todd Davis e il CFO Tavo Espinoza e riguarderanno la strategia, l'attività di investimento, il portafoglio royalty e le prospettive finanziarie a lungo termine.
Interverrà come relatore l'ospite Scott Plesha, CEO del partner Pelthos Therapeutics, che discuterà il recente lancio di ZELSUVMI (berdazimer) gel topico 10,3%, descritto come il primo trattamento a domicilio approvato dalla FDA per la mollusco contagioso. Sarà disponibile una diretta streaming e una replica sul sito di relazioni con gli investitori di Ligand, e gli investitori potranno registrarsi all'evento online.
Ligand (Nasdaq: LGND) celebrará su Investor Day anual el 9 de diciembre de 2025 en Nueva York, en The Harvard Club, de 10:30 a.m. a 12:00 p.m. ET. Las presentaciones de la dirección incluirán al CEO Todd Davis y al CFO Tavo Espinoza, y cubrirán la estrategia, la actividad de inversión, la cartera de regalías y las perspectivas financieras a largo plazo.
El orador invitado Scott Plesha, CEO de nuestro socio Pelthos Therapeutics, discutirá el reciente lanzamiento de ZELSUVMI (berdazimer) gel tópico 10.3%, descrito como el primer tratamiento en casa aprobado por la FDA para el molusco contagioso. Se podrá ver una webcast en vivo y la repetición en el sitio web de relaciones con inversores de Ligand, y los inversores podrán registrarse para el evento en línea.
Ligand (Nasdaq: LGND)는 2025년 12월 9일 뉴욕시 하버드클럽에서 동부 표준시 10:30~12:00에 연례 Investor Day를 개최합니다. 경영진 발표에는 CEO Todd Davis와 CFO Tavo Espinoza가 포함되며 전략, 투자 활동, 로열티 포트폴리오, 및 장기 재무 전망을 다룰 예정입니다.
파트너 Pelthos Therapeutics의 CEO인 게스트 스피커 Scott Plesha가 ZELSUVMI (berdazimer) 톡톡 제형 10.3%의 최근 출시를 논의할 것이며, 이는 FDA가 승인한 가정용 치료제 중 첫 번째 사례로 molluscum contagiosum으로 설명됩니다. 라이브 웹캐스트와 재방송이 Ligand의 투자자 관계 웹사이트에서 제공되며, 투자자들은 온라인으로 행사에 등록할 수 있습니다.
Ligand (Nasdaq: LGND) tiendra sa Journée Investisseurs annuelle le 9 décembre 2025 à New York, au The Harvard Club, de 10 h 30 à 12 h 00 (HE). Les présentations de la direction incluront le PDG Todd Davis et le CFO Tavo Espinoza et couvriront la stratégie, l’activité d’investissement, le portefeuille de redevances et les perspectives financières à long terme.
L’orateur invité Scott Plesha, PDG de notre partenaire Pelthos Therapeutics, discutera du récent lancement de ZELSUVMI (berdazimer) gel topique 10,3%, décrit comme le premier traitement à domicile approuvé par la FDA pour la molluscum contagiosum. Un webcast en direct et une rediffusion seront disponibles sur le site des relations investisseurs de Ligand, et les investisseurs pourront s’inscrire à l’événement en ligne.
Ligand (Nasdaq: LGND) wird am 9. Dezember 2025 in New York City, The Harvard Club, von 10:30 Uhr bis 12:00 Uhr ET seinen jährlichen Investorentag abhalten. Management-Präsentationen werden CEO Todd Davis und CFO Tavo Espinoza umfassen und die Strategie, Investitionstätigkeit, Royalties-Portfolio sowie den langfristigen finanziellen Ausblick behandeln.
Gastredner Scott Plesha, CEO unseres Partners Pelthos Therapeutics, wird die kürzliche Einführung von ZELSUVMI (berdazimer) Topisches Gel 10,3% diskutieren, das als erstes von der FDA zugelassenes Heimtherapieprodukt für Molluscum contagiosum beschrieben wird. Ein Live-Webcast und eine Wiederholung werden auf Ligands Investor-Relations-Website verfügbar sein, und Investoren können sich online für die Veranstaltung registrieren.
Ligand (Nasdaq: LGND) ستعقد يوماً للمستثمرين السنوي في 9 ديسمبر 2025 في مدينة نيويورك بمقر The Harvard Club من الساعة 10:30 صباحاً حتى 12:00 ظهرًا بتوقيت شرق الولايات المتحدة. ستشمل عروض الإدارة الرئيس التنفيذي تود ديفيس والمدير المالي تافو espinoza وستغطي استراتيجية الشركة، ونشاط الاستثمار، ومحفظة العوائد، وتوقعات مالية طويلة الأجل.
سيقدم المتحدث الضيف سكوت بليشيا، الرئيس التنفيذي لشركة Pelthos Therapeutics الشريك، نقاشاً حول الإطلاق الأخير لـ ZELSUVMI (berdazimer) جل موضعي 10.3%، الذي يوصف بأنه أول علاج منزلي معتمد من FDA لعلاج Molluscum contagiosum. سيكون هناك بث مباشر وإعادة بث متاحان على موقع العلاقات with investors لشركة Ligand، ويمكن للمستثمرين التسجيل للحدث عبر الإنترنت.
Ligand (Nasdaq: LGND) 将于 2025年12月9日 在纽约市的 The Harvard Club 举行年度投资者日，时间为 美东时间上午10:30至12:00。管理层演讲将包括 CEO Todd Davis 和 CFO Tavo Espinoza，并将涵盖公司的 战略、投资活动、特许权资产组合，以及长期财务展望。
特邀发言人 Pelthos Therapeutics 的 CEO Scott Plesha 将讨论最近推出的 ZELSUVMI (berdazimer) 局部凝胶 10.3%，被描述为 FDA 批准的首个居家治疗 Molluscum contagiosum。将通过 Ligand 的投资者 relations 网站提供现场网络直播与回放，投资者可以在线注册参加本次活动。
- None.
- None.
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a.m. to 12:00 p.m. Eastern Time at The Harvard Club.
The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Scott Plesha, CEO of partner Pelthos Therapeutics, will be a guest speaker at the event and will discuss the recent launch of ZELSUVMI™ (berdazimer) topical gel
A live webcast of the event will be accessible through Ligand’s Investor Relations website at investor.ligand.com. A webcast replay will be available following the conclusion of the event.
Investors and analysts can register for the event here.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When and where is Ligand (LGND) Investor Day on December 9, 2025?
Who will present at Ligand (LGND) Investor Day on December 9, 2025?
What topics will Ligand (LGND) cover at the December 9, 2025 Investor Day?
Will Ligand (LGND) provide a webcast for the December 9, 2025 Investor Day?
What will Pelthos CEO Scott Plesha discuss at Ligand (LGND) Investor Day?
